News

A review published in Therapeutic Advances in Hematology summarized the treatment landscape of newly diagnosed and relapsed and refractory MCL.

Real-world evidence from US community-based oncology practices supports the adoption of bevacizumab-awwb for treating patients with metastatic colorectal cancer.

Findings from a qualitative study at the Mayo Clinic suggest that patients with ovarian cancer are willing to adhere to oral olaparib therapy long term.

Findings from a recent study suggest that patients with CLL with atrial fibrillation may be at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke.

Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

Study findings report no clinically meaningful differences in febrile neutropenia incidence, HCRU, or costs between on-body injector and prefilled syringe methods of pegfilgrastim administration.

Patients with platinum-sensitive, recurrent ovarian cancer whose disease progressed following olaparib maintenance experienced poor response to subsequent platinum-based chemotherapy, according to a recent study.

A panel convened by leading organizations formulated recommendations for role, timing, and sequencing of blood and bone marrow transplantation and CAR-T therapy for newly diagnosed and relapsed/refractory MCL.

Study findings show the addition of isatuximab to pomalidomide and dexamethasone extended OS compared to pomalidomide and dexamethasone in lenalidomide-refractory and proteasome inhibitor-refractory or relapsed MM.

Neither daratumumab nor bortezomib added to lenalidomide plus dexamethasone are cost-effective vs lenalidomide and dexamethasone alone for patients with newly diagnosed MM, according to a recent study.